561 related articles for article (PubMed ID: 11717451)
1. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
[TBL] [Abstract][Full Text] [Related]
2. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E
J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670
[TBL] [Abstract][Full Text] [Related]
3. Structural conservation of the pores of calcium-activated and voltage-gated potassium channels determined by a sea anemone toxin.
Rauer H; Pennington M; Cahalan M; Chandy KG
J Biol Chem; 1999 Jul; 274(31):21885-92. PubMed ID: 10419508
[TBL] [Abstract][Full Text] [Related]
4. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
Wulff H; Calabresi PA; Allie R; Yun S; Pennington M; Beeton C; Chandy KG
J Clin Invest; 2003 Jun; 111(11):1703-13. PubMed ID: 12782673
[TBL] [Abstract][Full Text] [Related]
5. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
6. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.
Beeton C; Wulff H; Singh S; Botsko S; Crossley G; Gutman GA; Cahalan MD; Pennington M; Chandy KG
J Biol Chem; 2003 Mar; 278(11):9928-37. PubMed ID: 12511563
[TBL] [Abstract][Full Text] [Related]
7. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Norton RS; Pennington MW; Wulff H
Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
[TBL] [Abstract][Full Text] [Related]
8. Potassium channels as therapeutic targets for autoimmune disorders.
Wulff H; Beeton C; Chandy KG
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):640-7. PubMed ID: 14579513
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences.
Ghanshani S; Wulff H; Miller MJ; Rohm H; Neben A; Gutman GA; Cahalan MD; Chandy KG
J Biol Chem; 2000 Nov; 275(47):37137-49. PubMed ID: 10961988
[TBL] [Abstract][Full Text] [Related]
10. Different calcium influx characteristics upon Kv1.3 and IKCa1 potassium channel inhibition in T helper subsets.
Orbán C; Bajnok A; Vásárhelyi B; Tulassay T; Toldi G
Cytometry A; 2014 Jul; 85(7):636-41. PubMed ID: 24827427
[TBL] [Abstract][Full Text] [Related]
11. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
12. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
13. Potassium channels in T lymphocytes: therapeutic targets for autoimmune disorders?
Vianna-Jorge R; Suarez-Kurtz G
BioDrugs; 2004; 18(5):329-41. PubMed ID: 15377175
[TBL] [Abstract][Full Text] [Related]
14. The effects of Kv1.3 and IKCa1 potassium channel inhibition on calcium influx of human peripheral T lymphocytes in rheumatoid arthritis.
Toldi G; Bajnok A; Dobi D; Kaposi A; Kovács L; Vásárhelyi B; Balog A
Immunobiology; 2013 Mar; 218(3):311-6. PubMed ID: 22705192
[TBL] [Abstract][Full Text] [Related]
15. Selective blockade of the intermediate-conductance Ca2+-activated K+ channel suppresses proliferation of microvascular and macrovascular endothelial cells and angiogenesis in vivo.
Grgic I; Eichler I; Heinau P; Si H; Brakemeier S; Hoyer J; Köhler R
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):704-9. PubMed ID: 15662023
[TBL] [Abstract][Full Text] [Related]
16. [Ion channels and demyelination: basis of a treatment of experimental autoimmune encephalomyelitis (EAE) by potassium channel blockers].
Devaux J; Beeton C; Béraud E; Crest M
Rev Neurol (Paris); 2004 May; 160(5 Pt 2):S16-27. PubMed ID: 15269656
[TBL] [Abstract][Full Text] [Related]
17. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators.
Vennekamp J; Wulff H; Beeton C; Calabresi PA; Grissmer S; Hänsel W; Chandy KG
Mol Pharmacol; 2004 Jun; 65(6):1364-74. PubMed ID: 15155830
[TBL] [Abstract][Full Text] [Related]
18. [Change of CCR7 and CD45RA after blocking of Kv1.3 potassium channel of CD4+ T lymphocytes in multiple sclerosis].
Ren XT; Wu WP; Xu QG; Huang DH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1896-9. PubMed ID: 19040002
[TBL] [Abstract][Full Text] [Related]
19. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis.
Köhler R; Wulff H; Eichler I; Kneifel M; Neumann D; Knorr A; Grgic I; Kämpfe D; Si H; Wibawa J; Real R; Borner K; Brakemeier S; Orzechowski HD; Reusch HP; Paul M; Chandy KG; Hoyer J
Circulation; 2003 Sep; 108(9):1119-25. PubMed ID: 12939222
[TBL] [Abstract][Full Text] [Related]
20. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity.
Wulff H; Knaus HG; Pennington M; Chandy KG
J Immunol; 2004 Jul; 173(2):776-86. PubMed ID: 15240664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
